Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 13/20 | 0.91 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5911874 | 0.95 | S1PR2 (1.00) | S1PR2GRIN2BUSP2CYP2C9CYP1A2 | |
| SCHEMBL5912459 | 0.90 | S1PR2 (0.78) | S1PR2GRIN2BUSP2CYP2C9CYP1A2 | |
| SCHEMBL5912278 | 0.89 | S1PR2 (0.88) | S1PR2GRIN2BUSP2CYP2C9CYP1A2 | |
| SCHEMBL5912027 | 0.89 | S1PR2 (0.74) | S1PR2GRIN2BUSP2CYP2C9CYP1A2 | |
| SCHEMBL5912178 | 0.89 | S1PR2 (0.73) | S1PR2GRIN2BUSP2CYP2C9CYP1A2 | |
| SCHEMBL5912444 | 0.88 | S1PR2 (0.86) | S1PR2GRIN2BUSP2CYP2C9CYP1A2 | |
| SCHEMBL5912723 | 0.88 | S1PR2 (1.00) | S1PR2GRIN2BUSP2CYP2C9CYP1A2 | |
| SCHEMBL5911973 | 0.88 | S1PR2 (1.00) | S1PR2USP2CYP2C9CYP1A2TRPM8 | |
| SCHEMBL5912435 | 0.87 | S1PR2 (0.85) | S1PR2GRIN2BUSP2CYP2C9CYP1A2 | |
| SCHEMBL5912301 | 0.86 | S1PR2 (0.70) | S1PR2GRIN2BUSP2CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2508204-B1 | Remedies for diseases caused by vascular contraction or dilation | ONO PHARMACEUTICAL CO (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-8765783-B2 | Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation | ONO PHARMACEUTICALS CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-1522314-B1 | REMEDIES FOR DISEASES CAUSED BY VASCULAR CONTRACTION OR DILATION | ONO PHARMACEUTICAL CO (JP) | 2014-03-05 | — | — | EP | disclosed |
| EP-2508204-A2 | Remedies for diseases caused by vascular contraction or dilation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20060148844-A1 | Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation | ONO PHARMACEUTICAL CO., LTD | 2006-07-06 | — | — | US | disclosed |
| EP-1522314-A1 | REMEDIES FOR DISEASES CAUSED BY VASCULAR CONTRACTION OR DILATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148844-A1 | Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation | EDNRA, EDNRB, CACNG5 | S1PR2 480/4885GRIN2B 605/4885USP2 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.